德琪医药(06996)逆市升4.48% 机构料其和翰森制药合作有利于加速塞利尼索的医院覆盖和市场渗透

凤凰网港股2023-08-14

德琪医药(06996)逆市上扬，截至发稿，报1.4港元，涨4.48%，成交额115.68万港元。交银发研报指，德琪医药就塞利尼索国内商业化和翰森制药达成协议。该行指，翰森制药拥有丰富的血液肿瘤用药商业化和医保谈判经验。该行认为，本次合作有利于加速塞利尼索的医院覆盖和市场渗透，并有助于公司节约营销成本。该行上调公司2023-25E收入预测至4.1亿/7.7亿/10.5亿元，以反映新增合作收入。该行继续基于DCF模型对公司估值，得到最新目标价4.60港元，维持买入评级。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2359000206?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-08-14 13:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2359000206","market":"hk","top_or_hot":-1,"title":"德琪医药(06996)逆市升4.48% 机构料其和翰森制药合作有利于加速塞利尼索的医院覆盖和市场渗透","media":"凤凰网港股","content":"<html><body><p>德琪医药(06996)逆市上扬，截至发稿，报1.4港元，涨4.48%，成交额115.68万港元。交银发研报指，德琪医药就塞利尼索国内商业化和<a href=\"https://laohu8.com/S/03692\">翰森制药</a>达成协议。该行指，翰森制药拥有丰富的血液肿瘤用药商业化和医保谈判经验。该行认为，本次合作有利于加速塞利尼索的医院覆盖和市场渗透，并有助于公司节约营销成本。该行上调公司2023-25E收入预测至4.1亿/7.7亿/10.5亿元，以反映新增合作收入。该行继续基于DCF模型对公司估值，得到最新目标价4.60港元，维持买入评级。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>德琪医药(06996)逆市升4.48% 机构料其和翰森制药合作有利于加速塞利尼索的医院覆盖和市场渗透</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n德琪医药(06996)逆市升4.48% 机构料其和翰森制药合作有利于加速塞利尼索的医院覆盖和市场渗透\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-14 13:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://hknews.szfuit.com/newRssInfo/feed?original_id=1327e9c63b9514af112a10a98fcd0f80><strong>凤凰网港股</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>德琪医药(06996)逆市上扬，截至发稿，报1.4港元，涨4.48%，成交额115.68万港元。交银发研报指，德琪医药就塞利尼索国内商业化和翰森制药达成协议。该行指，翰森制药拥有丰富的血液肿瘤用药商业化和医保谈判经验。该行认为，本次合作有利于加速塞利尼索的医院覆盖和市场渗透，并有助于公司节约营销成本。该行上调公司2023-25E收入预测至4.1亿/7.7亿/10.5亿元，以反映新增合作收入。该行...</p>\n\n<a href=\"http://hknews.szfuit.com/newRssInfo/feed?original_id=1327e9c63b9514af112a10a98fcd0f80\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=1327e9c63b9514af112a10a98fcd0f80","article_id":"2359000206","we_media_id":"1002821290","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2359000206","pubTimestamp":1691991202,"sourceInfo":null,"weMediaInfo":{"media_name":"凤凰网港股","introduction":"凤凰网港股","home_visible":1,"id":"1002821290","head_image":"https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817"},"summary":"德琪医药(06996)逆市上扬，截至发稿，报1.4港元，涨4.48%，成交额115.68万港元。交银发研报指，德琪医药就塞利尼索国内商业化和翰森制药达成协议。该行指，翰森制药拥有丰富的血液肿瘤用药商业化和医保谈判经验。该行认为，本次合作有利于加速塞利尼索的医院覆盖和市场渗透，并有助于公司节约营销成本。该行上调公司2023-25E收入预测至4.1亿/7.7亿/10.5亿元，以反映新增合作收入。该行继续基于DCF模型对公司估值，得到最新目标价4.60港元，维持买入评级。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1583":"高瓴概念","03692":"翰森制药","BK1589":"北水核心资产","06996":"德琪医药-B","BK1191":"制药"},"translate_title":"Deqi Medicine (06996) rose 4.48% against the market. The organization expects that its cooperation with Hansen Pharmaceutical will help accelerate the hospital coverage and market penetration of Celineso","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1,"06996":1},"content_text":"德琪医药(06996)逆市上扬，截至发稿，报1.4港元，涨4.48%，成交额115.68万港元。交银发研报指，德琪医药就塞利尼索国内商业化和翰森制药达成协议。该行指，翰森制药拥有丰富的血液肿瘤用药商业化和医保谈判经验。该行认为，本次合作有利于加速塞利尼索的医院覆盖和市场渗透，并有助于公司节约营销成本。该行上调公司2023-25E收入预测至4.1亿/7.7亿/10.5亿元，以反映新增合作收入。该行继续基于DCF模型对公司估值，得到最新目标价4.60港元，维持买入评级。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2359000206"}